SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-138646
Filing Date
2020-12-22
Accepted
2020-12-22 17:15:21
Documents
13
Period of Report
2020-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2039168d1_8k.htm   iXBRL 8-K 31022
2 EXHIBIT 10.1 tm2039168d1_ex10-1.htm EX-10.1 423983
  Complete submission text file 0001104659-20-138646.txt   700433

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ymab-20201217.xsd EX-101.SCH 3178
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ymab-20201217_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ymab-20201217_pre.xml EX-101.PRE 22705
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2039168d1_8k_htm.xml XML 3709
Mailing Address 750 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 750 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 201408953
SIC: 2834 Pharmaceutical Preparations